Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 11.8% year on year to $3.44 billion. On the other hand, the company’s full-year revenue guidance of $13.2 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $4.76 per share was 0.5% below analysts’ consensus estimates.
Is now the time to buy VRTX? Find out in our full research report (it’s free for active Edge members).
Vertex Pharmaceuticals (VRTX) Q3 2026 highlights:
- Revenue $3.44 billion vs S&P analysts’ estimates of $3.42 billion (11.8% year-on-year growth, 0.7% beat)
- Adjusted EPS $4.76 vs S&P analysts’ expectations of $4.78 (0.5% miss)
- Adjusted operating income $1.41 billion vs analyst estimates of $1.44 billion (41% margin, 2.2% miss)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $13.2 billion at the midpoint from $13.15 billion
- Operating margin 20.7%, down from 38.6% in the same quarter last year
- Market capitalization $140.2 billion
StockStory’s take
Vertex Pharmaceuticals’ third quarter featured strong top-line growth, as management pointed to expanding contributions from newer therapies, ongoing adoption of its cystic fibrosis (CF) treatments, and initial revenue from the Crinetics acquisition. CEO Reshma Kewalramani highlighted balanced growth across both U.S. and international markets, with the company’s portfolio now spanning four commercial pillars. Management underscored execution in launches like ALYFTREK for CF and CASGEVY for rare blood disorders, while also noting operational investments related to commercial infrastructure and integration costs from Crinetics.
Looking forward, Vertex’s updated guidance reflects expectations for continued diversification, with management emphasizing the upcoming launch of povetacicept in IgA nephropathy as a major milestone. Kewalramani described the company’s priorities as advancing its late-stage pipeline, scaling newly acquired endocrinology assets, and executing global launches. The company remains focused on broadening access for products like JOURNAVX and expanding indications for established therapies. CFO Charlie Wagner cautioned that higher operating expenses, primarily from integration and commercial investments, will persist into next year as Vertex aims to maintain momentum across multiple disease areas.
Key insights from management’s remarks
Management attributed third quarter performance to the continued uptake of new therapies, broad-based international expansion, and the initial integration of Crinetics’ operations.
- ALYFTREK drives CF growth: The once-daily ALYFTREK therapy saw expanded adoption, supported by reimbursement gains in 31 countries and label expansions targeting new patient populations. Management sees further growth potential from younger patient approvals and rare mutation indications.
- Rare disease launches gain traction: CASGEVY, for sickle cell disease and beta thalassemia, continued to scale with over 200 infusions completed this year. JOURNAVX, an oral analgesic for moderate to severe pain, became the top prescribed branded oral analgesic in the U.S., reflecting successful conversion of prescribers and broad payer access.
- Crinetics integration underway: The acquisition brought PALSONIFY, an oral acromegaly therapy, contributing initial revenue and positioning Vertex for growth in rare endocrinology. Management highlighted a focus on increasing repeat prescribing and preparing for international launches.
- Pipeline progress across disease areas: Late-stage programs in renal (povetacicept, inaxaplin) and type 1 diabetes (VX-017 cell therapy) advanced, with management citing upcoming regulatory milestones and data readouts as pivotal for future growth.
- Elevated investment in commercial capabilities: Operating expenses rose as Vertex expanded its field teams, especially in support of upcoming launches in nephrology and endocrinology, and maintained patient support programs to facilitate access and adoption.
Drivers of future performance
Vertex’s outlook is shaped by new product launches, ongoing label expansions, and increased investment in commercial infrastructure.
- Global launch of povetacicept: Management is preparing for the anticipated approval and launch of povetacicept in IgA nephropathy, emphasizing its patient-friendly auto-injector and potential for broad adoption in a large unmet market. Regulatory submissions in additional countries are planned as data matures.
- Pipeline readouts and expansion: Key milestones include interim data from the AMPLITUDE trial of inaxaplin in AMKD (a rare kidney disease) and advancing VX-017 for type 1 diabetes. Management believes success in these programs could significantly expand Vertex’s addressable markets and add new revenue streams.
- Commercial investment and integration costs: Increased operating expenses are expected to continue as the company integrates Crinetics, ramps up field teams for upcoming launches, and maintains support programs like JOURNAVX’s patient assistance initiative. Management views these investments as necessary for sustaining long-term growth but acknowledged they will weigh on margins in the near term.
Catalysts in upcoming quarters
In the coming quarters, our analysts will be monitoring (1) the approval and launch trajectory for povetacicept in IgA nephropathy and its market uptake, (2) the pace and impact of further ALYFTREK label expansions and international reimbursement deals in CF, and (3) upcoming clinical data from key pipeline assets, particularly inaxaplin for AMKD and VX-017 for type 1 diabetes. Execution on Crinetics integration and ramping commercial infrastructure will also be important for tracking Vertex’s diversification.
Vertex Pharmaceuticals currently trades at $556.50, in line with $553.15 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.